|
Volumn 31, Issue 29, 2013, Pages 3721-
|
GnRH agonist for the prevention of chemotherapy-induced ovarian failure in lymphoma
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ESTRADIOL;
GONADORELIN AGONIST;
MUELLERIAN INHIBITING FACTOR;
FOLLITROPIN;
GONADORELIN;
TRIPTORELIN;
ADVERSE DRUG REACTION;
BREAST CANCER;
CHEMOTHERAPY INDUCED OVARIAN FAILURE;
FEMALE FERTILITY;
FERTILITY PRESERVATION;
HODGKIN DISEASE;
HUMAN;
LETTER;
LYMPHOMA;
MULTICENTER STUDY (TOPIC);
OVARIAN PRESERVATION;
OVARY FUNCTION;
OVARY INSUFFICIENCY;
PHASE 3 CLINICAL TRIAL (TOPIC);
PREGNANCY RATE;
PREMATURE OVARIAN FAILURE;
PREMENOPAUSE;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
BLOOD;
CHEMICALLY INDUCED DISORDER;
DRUG POTENTIATION;
FEMALE;
NOTE;
AGONISTS;
CHEMICALLY INDUCED;
PRIMARY OVARIAN INSUFFICIENCY;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ESTRADIOL;
FEMALE;
FOLLICLE STIMULATING HORMONE;
GONADOTROPIN-RELEASING HORMONE;
HUMANS;
LYMPHOMA;
PREMENOPAUSE;
PRIMARY OVARIAN INSUFFICIENCY;
TRIPTORELIN PAMOATE;
|
EID: 84891535485
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2012.47.8222 Document Type: Letter |
Times cited : (12)
|
References (5)
|